Deerfield Management Company, L.P. (Series C) Kymera Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 593,000 shares of KYMR stock, worth $19.3 Million. This represents 0.59% of its overall portfolio holdings.
Number of Shares
593,000Holding current value
$19.3 Million% of portfolio
0.59%Shares
1 transactions
Others Institutions Holding KYMR
# of Institutions
186Shares Held
65.6MCall Options Held
49.6KPut Options Held
17K-
Price T Rowe Associates Inc Baltimore, MD6.87MShares$224 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$195 Million2.67% of portfolio
-
Wellington Management Group LLP Boston, MA5.31MShares$173 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$168 Million7.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.15MShares$168 Million3.02% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $1.78B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...